FDA warns Shantou S.E.Z. Baojie Industry over inadequate CGMP and component testing for OTC drug products, leading to Import Alert 66-40.
What happened
FDA inspected the Shantou, Guangdong, China drug manufacturing facility from August 26 to 30, 2024. The inspection found inadequate identity and conformity testing of incoming components, including components at higher risk of contamination, despite a prior commitment to test every lot, plus inadequate production controls, stability testing, and quality-unit oversight. FDA placed products offered for import from the firm on Import Alert 66-40 on April 9, 2025.
What FDA found
The firm did not test each incoming component lot for identity and conformity and relied on supplier certificates without validating the suppliers’ test results.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm lacked adequate written production and process controls for a system it uses as a drug component and for cleaning equipment, with insufficient validation and monitoring.
21 CFR 211.100(a)The firm’s stability program was inadequate because it used only odor, color, and appearance checks and lacked chemical and microbial testing to support labeled expiration dates.
21 CFR 211.166(a)The quality control unit failed to oversee incoming component testing, production procedures, stability testing, product reviews, and test-method verification.
21 CFR 211.22
What FDA wants
FDA tells the firm to respond in writing within 15 working days with corrective actions and supporting data, including high-risk component test results within 30 calendar days, a risk assessment for products within expiry, and remediation plans for the system, stability program, and quality unit. If it intends to resume U.S. manufacturing, FDA recommends a qualified CGMP consultant.
Who should pay attention
- U.S. distributors and brands selling OTC drug products made by this firm
- drug manufacturers that buy high-risk components or rely on supplier test reports
- quality teams responsible for incoming component testing and supplier qualification
This is a summary. Read the original letter on fda.gov.